Andere Sprachen BioInvent International AB

Aktien

A2QJRW

SE0015244520

BINV

Verzögert Nasdaq Stockholm Andere Börsenplätze 12:59:33 30.04.2024			% 5 Tage	% 1. Jan.
26 ^SEK	+2,77 %		+11,59 %	+37,13 %

30.04.	BioInvent kündigt Evaluierung der Attana-Technologie an	CI
24.04.	BioInvent International AB (publ) meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioInvent evaluating Attana Technology	30.04.
BioInvent Announces Evaluating Attana Technology	30.04.
BioStock: BioInvent selected to present at ASCO in Chicago	29.04.
BioInvent International AB, Interim report January-March 2024	25.04.
BioInvent Q1 2024 - Approaching Catalysts	25.04.
BioInvent to Present Clinical Data from its two leading assets at ASCO 2024	24.04.
BioInvent International AB: Interim report January-March 2024	24.04.
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	24.04.
BioInvent International AB publishes Annual Report 2023	04.04.
BioStock: BioInvent deepens collaboration with MSD	04.04.
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	03.04.
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	03.04.
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02.04.
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02.04.
Notice to Annual General Meeting in BioInvent International AB	27.03.
BioStock: BioInvent's CEO comments on the study success in China	11.03.
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	06.03.
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	05.03.
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	05.03.
BioInvent International AB Year-end report January 1, December 31, 2023	23.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioInvent International AB

Aktien

A2QJRW

SE0015244520

BINV

Andere Sprachen

Filter